Kitae Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kitae Kim has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
Yutaka Furukawa
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
9 shared publications- Yutaka Furukawa
Kobe City Medical Center General Hospital
9 shared publications Makoto Kinoshita
Kobe City Med Ctr Gen Hosp, Dept Cardiovasc Med, Kobe, Japan
6 shared publications- Shuichiro Kaji
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
6 shared publications - Takeshi Kitai
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
6 shared publications Madoka Sano
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
5 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (9)
The biological interplay between aortic stenosis and transthyretin cardiac amyloidosis
- 27 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (9)
Open AccessThe biological interplay between aortic stenosis and transthyretin cardiac amyloidosis
- Open Access
- 14 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (34) , 109310
Leaflet-to-Ring Edge-to-Edge Repair With Paravalvular Leak Closure for Dehisced Surgical Mitral Annuloplasty
- 14 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (34) , 109310
Open AccessLeaflet-to-Ring Edge-to-Edge Repair With Paravalvular Leak Closure for Dehisced Surgical Mitral Annuloplasty
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1681-1682
UNICORN for Native Transcatheter Aortic Valve Replacement in a Bicuspid Aortic Valve
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1681-1682
UNICORN for Native Transcatheter Aortic Valve Replacement in a Bicuspid Aortic Valve
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2043-2058
Pulmonary Artery Pulsatility Index and Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Replacement
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2043-2058
Pulmonary Artery Pulsatility Index and Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Replacement
- Open Access
- 18 January 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (9) , 106791
Fluoroscopic Risk Stratification of New-Onset Conduction Disturbances After Transcatheter Tricuspid Valve Replacement
- 18 January 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (9) , 106791
Open AccessFluoroscopic Risk Stratification of New-Onset Conduction Disturbances After Transcatheter Tricuspid Valve Replacement
- Open Access
- 3 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101956
Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis
- 3 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101956
Open AccessProlonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis
- 19 March 2025
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 52 (2) , 197-207
Long-term outcomes of abdominal aortic aneurysm screening in patients undergoing transthoracic echocardiography
Purpose Reports on the usefulness of abdominal aortic aneurysm (AAA) screening during transthoracic echocardiography (TTE) in Japan are limited. This study aimed to describe the prevalence of AAA among patients who underwent routine screening during TTE, as well as the long-term clinical outcomes of patients in whom AAA was detected. Methods We screened 46,353 consecutive patients who underwent TTE for suspected cardiac disease at our institution. Among these, a total of 1133 patients were identified as having AAA, defined as an abdominal aorta diameter of 30 mm or greater. After excluding patients with prior aortic surgery, including endovascular repair (n = 104), those with known AAA (n = 569), and those with known aortic dissection (n = 25), the study population consisted of 435 patients, all diagnosed with AAA for the first time. Results The overall prevalence of AAA among patients undergoing TTE was 0.94%. The mean age was 76.8 years, and the study population was predominantly males (81.6%). The prevalence of AAA in patients under 60 years of age was low: 0.24% for men and 0.076% for women. The left atrial volume index was 43.8 ± 23.1 ml/m2, the left ventricular mass was 164.9 ± 52.0 g, and the diameter of the sinus of Valsalva was 32.6 ± 4.4 mm, all of which were numerically higher than the normal values observed in a healthy Japanese population. During the median follow-up period of 2.0 years, 43 surgical or endovascular repairs of AAA, six aorta-related deaths, and 90 all-cause deaths occurred. The cumulative incidence of surgical or endovascular repair of AAA was 5.3% at 1 year, 11.5% at 3 years, and 18.1% at 5 years. The cumulative incidence of aorta-related death was modest: 0.3% at 1 year, 0.8% at 3 years, and 1.6% at 5 years. Conclusion The prevalence of newly diagnosed AAA among patients who underwent routine screening during TTE for suspected cardiac disease was 0.94% in the Japanese population, with the majority being 60 years or older. Approximately 10% of patients diagnosed with AAA underwent surgical or endovascular repair during follow-up, suggesting that this approach may be effective in preventing deaths caused by AAA.
- 19 March 2025
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 52 (2) , 197-207
Long-term outcomes of abdominal aortic aneurysm screening in patients undergoing transthoracic echocardiography
Purpose Reports on the usefulness of abdominal aortic aneurysm (AAA) screening during transthoracic echocardiography (TTE) in Japan are limited. This study aimed to describe the prevalence of AAA among patients who underwent routine screening during TTE, as well as the long-term clinical outcomes of patients in whom AAA was detected. Methods We screened 46,353 consecutive patients who underwent TTE for suspected cardiac disease at our institution. Among these, a total of 1133 patients were identified as having AAA, defined as an abdominal aorta diameter of 30 mm or greater. After excluding patients with prior aortic surgery, including endovascular repair (n = 104), those with known AAA (n = 569), and those with known aortic dissection (n = 25), the study population consisted of 435 patients, all diagnosed with AAA for the first time. Results The overall prevalence of AAA among patients undergoing TTE was 0.94%. The mean age was 76.8 years, and the study population was predominantly males (81.6%). The prevalence of AAA in patients under 60 years of age was low: 0.24% for men and 0.076% for women. The left atrial volume index was 43.8 ± 23.1 ml/m2, the left ventricular mass was 164.9 ± 52.0 g, and the diameter of the sinus of Valsalva was 32.6 ± 4.4 mm, all of which were numerically higher than the normal values observed in a healthy Japanese population. During the median follow-up period of 2.0 years, 43 surgical or endovascular repairs of AAA, six aorta-related deaths, and 90 all-cause deaths occurred. The cumulative incidence of surgical or endovascular repair of AAA was 5.3% at 1 year, 11.5% at 3 years, and 18.1% at 5 years. The cumulative incidence of aorta-related death was modest: 0.3% at 1 year, 0.8% at 3 years, and 1.6% at 5 years. Conclusion The prevalence of newly diagnosed AAA among patients who underwent routine screening during TTE for suspected cardiac disease was 0.94% in the Japanese population, with the majority being 60 years or older. Approximately 10% of patients diagnosed with AAA underwent surgical or endovascular repair during follow-up, suggesting that this approach may be effective in preventing deaths caused by AAA.
- Top Cited PapersOpen Access
- 4 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (9) , 589-600
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
BACKGROUND: The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 32 institutions in Japan, we randomly assigned patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, in a 1:1 ratio, to receive either an 18-month or a 6-month rivaroxaban treatment. The primary end point was recurrent venous thromboembolism (VTE) at 18 months. The major secondary end point was major bleeding at 18 months according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that an 18-month treatment was superior to a 6-month treatment in terms of the primary end point. RESULTS: From February 2021 to March 2023, 179 patients were randomized, and after the exclusion of one patient who withdrew consent, 178 were included in the intention-to-treat population: 89 patients in the 18-month rivaroxaban group and 89 in the 6-month rivaroxaban group. The mean age was 65.7 years; 47% of the patients were men, and 12% had symptoms of PE at baseline. The primary end point of recurrent VTE occurred in 5 of the 89 patients (5.6%) in the 18-month rivaroxaban group and in 17 of the 89 (19.1%) in the 6-month rivaroxaban group (odds ratio, 0.25 [95% CI, 0.09–0.72]; P =0.01). Among 22 recurrent VTE, 5 patients presented with a symptomatic recurrent VTE; recurrent PE occurred in 11 patients, including 2 with main and 4 with lobar PEs; and recurrent deep vein thrombosis was seen in 11 patients, including 3 with proximal deep vein thromboses. The major secondary end point of major bleeding occurred in 7 of the 89 patients (7.8%) in the 18-month rivaroxaban group and in 5 of the 89 patients (5.6%) in the 6-month rivaroxaban group (odds ratio, 1.43 [95% CI, 0.44–4.70]; P =0.55). CONCLUSIONS: In patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, the 18-month rivaroxaban treatment was superior to the 6-month rivaroxaban treatment with respect to recurrent VTE events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04724460.
- 4 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (9) , 589-600
Top Cited PapersOpen AccessRivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
BACKGROUND: The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 32 institutions in Japan, we randomly assigned patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, in a 1:1 ratio, to receive either an 18-month or a 6-month rivaroxaban treatment. The primary end point was recurrent venous thromboembolism (VTE) at 18 months. The major secondary end point was major bleeding at 18 months according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that an 18-month treatment was superior to a 6-month treatment in terms of the primary end point. RESULTS: From February 2021 to March 2023, 179 patients were randomized, and after the exclusion of one patient who withdrew consent, 178 were included in the intention-to-treat population: 89 patients in the 18-month rivaroxaban group and 89 in the 6-month rivaroxaban group. The mean age was 65.7 years; 47% of the patients were men, and 12% had symptoms of PE at baseline. The primary end point of recurrent VTE occurred in 5 of the 89 patients (5.6%) in the 18-month rivaroxaban group and in 17 of the 89 (19.1%) in the 6-month rivaroxaban group (odds ratio, 0.25 [95% CI, 0.09–0.72]; P =0.01). Among 22 recurrent VTE, 5 patients presented with a symptomatic recurrent VTE; recurrent PE occurred in 11 patients, including 2 with main and 4 with lobar PEs; and recurrent deep vein thrombosis was seen in 11 patients, including 3 with proximal deep vein thromboses. The major secondary end point of major bleeding occurred in 7 of the 89 patients (7.8%) in the 18-month rivaroxaban group and in 5 of the 89 patients (5.6%) in the 6-month rivaroxaban group (odds ratio, 1.43 [95% CI, 0.44–4.70]; P =0.55). CONCLUSIONS: In patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, the 18-month rivaroxaban treatment was superior to the 6-month rivaroxaban treatment with respect to recurrent VTE events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04724460.
- Open Access
- 4 December 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (1) , 102720
Left Main Coronary Artery Ostial Stenosis Caused by Syphilitic Aortitis Presenting With Syncope
- 4 December 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (1) , 102720
Open AccessLeft Main Coronary Artery Ostial Stenosis Caused by Syphilitic Aortitis Presenting With Syncope
- 23 November 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 420, 132754
The role of D-dimer in hypertrophic cardiomyopathy requiring myectomy
- 23 November 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 420, 132754
The role of D-dimer in hypertrophic cardiomyopathy requiring myectomy